Two-year post-discharge costs of care among patients treated with transcatheter or surgical aortic valve replacement in Germany

Klaus Kaier1,2,4*, Frederike von Kampen2, Hardy Baumbach3, Constantin von zur Mühlen2, Philip Hehn1, Werner Vach1, Manfred Zehender2, Christoph Bode2 and Jochen Reinöhl2

Abstract

Background: This study presents data on post-discharge costs of care among patients treated with transcatheter or surgical aortic valve replacement over a two year period.

Methods: Based on a prospective clinical trial, post-discharge utilization of health services and status of assistance were collected for 151 elderly patients via 2250 monthly telephone interviews, valued using standardized unit costs and analysed using two-part regression models.

Results: At month 1 post-discharge, total costs of care are substantially elevated (monthly mean: €3506.7) and then remain relatively stable over the following 23 months (monthly mean: €622.3). As expected, the majority of these costs are related to in-hospital care (~98% in month 1 post-discharge and ~72% in months 2–24). Patients that died during follow-up were associated with substantially higher cost estimates of in-hospital care than those surviving the two-year study period, while patients’ age and other patient characteristics were of minor relevance. Estimated costs of outpatient care are lower at month 1 than during the rest of the study period, and not affected by the event of death during follow-up. The estimated costs of nursing care are, in contrast, much higher in year 2 than in year 1 and differ substantially by gender and type of procedure as well as by patients’ age. Overall, these monthly cost estimates add up to €10,352 for the first and €7,467.6 for the second year post-discharge.

Conclusions: Substantial cost increases at month 1 post-discharge and in case of death during follow-up are the main findings of the study, which should be taken into account in future economic evaluations on the topic. Application of standardized unit costs in combination with monthly patient interviews allows for a far more precise estimate of the variability in post-discharge health service utilization in this group of patients than the ones given in previous studies.

Trial registration: German Clinical Trial Register Nr. DRKS00000797.

Keywords: SAVR, TAVR, TAVI, Standardized unit costs, Two-part model, Patient-level data

JEL codes: I10, C24

* Correspondence: Kaier@imbi.uni-freiburg.de

1Institute for Medical Biometry and Statistics, Faculty of Medicine and Medical Center – University of Freiburg, Freiburg im Breisgau, Germany

2Department of Cardiology, Heart Center Freiburg University, Freiburg im Breisgau, Germany

Full list of author information is available at the end of the article

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Any economic evaluation in healthcare heavily relies on estimates regarding the health consequences associated with different treatment approaches. When it comes to estimating long-run resource utilization, it is not uncommon to calculate these values using readily available event probabilities and average unit costs that are assumed to apply uniformly to all patients. For elderly patients with multiple severe co-morbidities, however, it is useful to more granularly estimate the costs of care for patients with different diseases, and to study in greater detail how different types of costs vary both over time and for various patient and treatment characteristics of interest [1].

The prevalence of acquired aortic valve stenosis is on the rise in the aging populations of the developed countries [2, 3]. The choice of treatment for these patients, however, remains controversial [4, 5]. The gold standard in the treatment of aortic valve stenosis has long been surgical aortic valve replacement (SAVR) [6, 7]. Since 2007, however, transcatheter aortic valve replacement (TAVR) has become established as a new standard of care for inoperable and high-risk patients [8, 9]. Ever since, clinical complications and long-term outcomes of TAVR have been the subject of extensive clinical research [10–12].

There is a considerable basket of studies that report TAVR and/or SAVR-related costs during the initial episode of hospitalization [13–23], or estimate the post discharge costs of care using event probabilities and average unit costs from the existing literature [24–31], and/or adapted results from the landmark Placement of Aortic Transcatheter Valve trial (PARTNER) [20, 21, 29], which however focused exclusively on the US healthcare system. In addition, the length of follow-up of the existing studies is short, and existing long-run follow-up costs are estimates-based data collected from various sources.

The aim of the present study was to close this gap of knowledge by evaluating two-year costs of care among high-risk patients with severe symptomatic aortic valve stenosis. In detail, comprehensive monthly cost measurements were conducted over a two year period a part of the prospective, medical-economic TAVI Calculation of Costs Trial (TCCT).

Methods
Data collection
The TAVI Calculation of Costs Trial (TCCT) was designed as a prospective observational multicenter cohort study on elderly patients with symptomatic AS receiving either SAVR, TAVR, or best medical therapy (DRUG) [32].

This study is part of TCCT and was approved by the institutional ethics committee (Research Ethics Committee Albert-Ludwigs-Universität Freiburg, Germany ID: 52/11), and registered in the German Clinical Trial Register (ID: DRKS00000797). Over a two-year period, a total of 2250 monthly telephone interviews were conducted by study nurse with 151 elderly patients treated with either TAVR (n = 85) or SAVR (n = 66). All patients referred to our centers between April 2011 and October 2013 were considered for inclusion into the study. Age above 75 years was deliberately chosen as an inclusion criterion. All treatment decisions were made by a study-independent “heart team” of cardiac surgeons and cardiologists according to best clinical practice [32].

In addition, a total of 70 follow-up interviews were conducted with 6 patients receiving drug-based therapy (DRUG, N = 6). Due to a lack of comparability, however, all results of DRUG patients were excluded from the main manuscript, but added to the online appendix (see Additional file 1: Table S1 and Additional file 2: Table S2).

Calculating costs of care at the patient level
We applied a micro costing approach on the patient level. In detail, monthly records of medical resource utilization were used to calculate different costs of care for each patient-month separately. For visits at primary care physicians (€20.06) as well as medical emergency service or specialist consultants (€65.44), standardized unit costs from Bock et al. [2014] [33] were applied, representing costs as of 2011. For the small numbers of rescue services interventions, emergency admissions and outpatient hospital visits, however, no standardized unit costs were available and these consultations were therefore valued (at €222, €126 and €132, respectively) according to average expenditures or case specific reimbursement, as available. Episodes of hospitalization were valued according to documented hours of hospitalization in intensive care units (€1337.72 per 24 h) or general wards (€593.04 per 24 h), as suggested by Bock et al. [2014] [33]. The patients’ current status of assistance was valued according to the self-reported status of assistance and the documented care level in accordance with Bock et al. [2014] [33] as follows: Outpatient allowance for nursing care (€225, €430 and €685 for care level I, II and III), outpatient benefits in kind for nursing care (€440, €1040 and €1510 for care level I, II and III), inpatient short term care (€1923.61, €2340.29 and €2760.62 for care level I, II and III), inpatient long term care (€1782.38, €2224.93 and €2692.14 for care level I, II and III). Despite some minor inconsistencies in valuing every documented record of resource utilization, prices reflect 2011 values. Overall, four cost figures (costs of nursing care, costs of outpatient care, costs of in-
hospital care and total costs of care) were distinguished, aggregated for each month and patient and used for analysis. Please note that the sum of the different cost figures, the total costs of care, does not include any type of indirect medical costs and therefore represents the perspective of all health care payers (health insurances and sickness funds), only.

Statistical analysis
Skewed data is the main issue in statistical models in healthcare costs [34–36]. Beside the fact that the four cost figures were positively skewed, they were equal to zero during a considerable number of months because patients were not reliant on nursing care, did not see a physician and/or were not hospitalized in a given month. In order to accommodate these characteristics of the data, a two-part model approach was chosen for the regression analyses [37–39]. In two part models, a binary choice model is estimated for the probability of observing a zero versus positive outcome. Then, conditional on a positive outcome, an appropriate regression model is estimated for the positive outcome [40]. For part one of the applied models a logistic regression analysis was chosen to predict whether or not patients would utilize resources related to the respective costs figure. As recommended [36, 39, 41–44], a generalised linear model (GLM) with the log link and gamma distribution was chosen for the second part. In addition, the cluster option was used to address the fact that multiple monthly cost estimates are included in the dataset for the same patient. Marginal means from the combined models are shown on the raw scale (€ per month). This two-step procedure is used to first show the development of the monthly cost estimates over the two-year period by

Table 1 Patient characteristics and monthly parameters during two-year follow up

| Baseline characteristics of 151 patients |
|----------------------------------------|
| Age 82.06 ± 4.96                        |
| Logistic EuroSCORE 15.14 ± 9.91        |
| Female 58.3%                            |
| Patients aged 75–79 years 44.4%        |
| Patients aged 80–84 years 29.8%        |
| Patients aged ≥ 85 years 25.8%         |
| TAVR 56.3%                              |
| AVR 43.7%                               |
| Mean nursing care utilization during two-year follow up (N = 2250 patient months) |
| No documentation of nursing care 82.7%  |
| Allowance for nursing care (outpatient) 5.1% |
| Care benefits in kind (outpatient) 8.6% |
| Short term care (inpatient) 0.2%        |
| Long term care (inpatient) 3.4%         |
| Number of medical visits during two-year follow up (N = 2250 patient months) |
| Primary care physician 1568 € 20.06     |
| Medical emergency service 13 € 65.44    |
| Specialist consultant 368 € 65.44       |
| Rescue service 26 € 222                  |
| emergency admission 5 € 126             |
| outpatient hospital visit 103 € 132      |
| Temporal hospitalization 216 €1337.72 (ICU) |
|                                                                                       |
|                                                                                       |
|                                                                                       |
| Mean monthly costs and mortality during two-year follow up (N = 2250 patient months) |
| Total costs (mean sd) 801.8 € 3345.3 €   |
| Costs of in-hospital care (mean sd) 638.5 € 3233.9 €                               |
| Costs of outpatient care (mean sd) 33.9 € 47.3 €                                   |
| Costs of nursing care (mean sd) 129.4 € 387.4 €                                   |
| Mortality during follow-up 17.9%                                                  |
including time (in months) as a categorical covariate. Next, interaction terms between two covariates are included in order to separate the development of the monthly cost estimates across different patient groups. All analyses were performed using Stata 14 (Stata Corp., Texas. USA).

Results
Table 1 provides an overview of baseline patient characteristics. For the 2250 documented patient months, a total of 2299 medical visits were recorded, including 216 cases of temporal hospitalization. As expected, temporal hospitalization was associated with substantial costs. A total of 27 of the 151 patients died during follow up.

Figure 1 provides monthly cost estimates regarding the four cost figures over the two-year period. At month 1 post-discharge, costs of in-hospital care are substantially increased, reaching €3439.1 (95% CI €2338.1–€4540.1), compared to only €452.6 (CI €316.9–€588.3) during the other months in the study period. In contrast, costs of outpatient care and costs of nursing care are lower for month 1 post-discharge, presumably due to the fact that many patients were discharged to another hospital directly.

Table 2 provides detailed estimates for costs of nursing care, costs of outpatient care, costs of in-hospital care and total costs of care and their value at month 1 post-discharge as well as during the other months in the study period. The costs of nursing care were separated into year 1 and year 2 figures due to their temporal development shown in Fig. 2.

Calculating the one-year total cost estimates from the predictions shown in Table 2 returns a mean of €10,352 for the first and €7467.6 for the second year post-discharge. As expected, the majority of these costs are related to in-hospital care, and the related cost estimates are thus also higher in year 1 (€8417.7) than in year 2 (€5431.2). In contrast the costs of outpatient care

Fig. 1 Two year monthly total costs of care estimates for patients treated for aortic valve stenosis. a All Patients. b TAVR Patients. c AVR Patients
Table 2  Two year monthly cost estimates of patients treated for aortic valve stenosis

|                        | Total costs of care | Costs of in-hospital care | Costs of outpatient care | Costs of nursing care |
|------------------------|---------------------|---------------------------|--------------------------|----------------------|
|                        | Month 1             | Month 2–24                | Month 1                  | Month 2–24           | Month 1–12          | Month 13–24 |
| Overall mean           | 3506.7              | 622.3                     | 3439.1                   | 452.6                | 16.12              | 35.13       | 104.7       | 174.0 |
| (year 1: €402.6; year 2: €421.6) | (year 1: €2088.4; year 2: €2088.4) | (year 1: €1256.4; year 2: €1256.4) | | | | |
| Male                   | 3272.6              | 572.8                     | 3311.0                   | 441.0                | 17.60              | 37.33       | 67.99       | 113.7 |
| (year 1: €1806.8; year 2: €1806.8) | (year 1: €3348.1; year 2: €3348.1) | (year 1: €3169.858; year 2: €3169.858) | | | | |
| Female                 | 3660.0              | 685.9                     | 3512.9                   | 461.9                | 14.74              | 33.53       | 133.5       | 215.5 |
| (year 1: €2296.0; year 2: €2296.0) | (year 1: €4769840.9; year 2: €4769840.9) | (year 1: €2343476.4; year 2: €2343476.4) | | | | |
| TAVR                   | 4247.5              | 711.0                     | 3637.8                   | 481.2                | 16.19              | 34.66       | 141.2       | 227.4 |
| (year 1: €2472.9; year 2: €2472.9) | (year 1: €5244897.6; year 2: €5244897.6) | (year 1: €3143648.0; year 2: €3143648.0) | | | | |
| AVR                    | 2863.6              | 495.7                     | 3182.2                   | 411.3                | 16.19              | 35.78       | 56.03       | 94.47 |
| (year 1: €1640.3; year 2: €1640.3) | (year 1: €2649726.6; year 2: €2649726.6) | (year 1: €2203620.2; year 2: €2203620.2) | | | | |
| Patients aged 75–79 years | 2797.6              | 509.9                     | 3250.9                   | 407.7                | 15.85              | 35.28       | 28.92       | 46.92 |
| (year 1: €1453.1; year 2: €1453.1) | (year 1: €1854.2; year 2: €1854.2) | (year 1: €715399.1; year 2: €715399.1) | | | | |
| Patients aged 80–84 years | 4292.5              | 769.8                     | 4297.0                   | 560.3                | 15.47              | 35.77       | 114.5       | 173.3 |
| (year 1: €2073.1; year 2: €2073.1) | (year 1: €46151078.1; year 2: €46151078.1) | (year 1: €2987821.8; year 2: €2987821.8) | | | | |
| Patients aged ≥85 years | 3840.7              | 629.6                     | 3054.6                   | 385.8                | 17.03              | 34.17       | 231.1       | 336.4 |
| (year 1: €2313.3; year 2: €2313.3) | (year 1: €3419642.3; year 2: €3419642.3) | (year 1: €2127559.0; year 2: €2127559.0) | | | | |
| No death during follow-up | 301.4               | 500.7                     | 2735.9                   | 351.0                | 15.95              | 34.45       | 99.50       | 171.2 |
| (year 1: €2013.5; year 2: €2013.5) | (year 1: €3686328.8; year 2: €3686328.8) | (year 1: €2354966.1; year 2: €2354966.1) | | | | |
| Death during follow-up | 9154.3              | 1703.2                    | 8134.6                   | 1285.9               | 15.93              | 41.49       | 137.8       | 232.8 |
| (year 1: €3610.5; year 2: €3610.5) | (year 1: €4194412074.8; year 2: €4194412074.8) | (year 1: €64161930.2; year 2: €64161930.2) | | | | |
| N                      | 2250                | 2250                      | 2250                     | 2250                 | 2250               | 2250        | 2250        | 2250 |

Separate two part models, with one (only time: month 1 vs. month 2–24, or month 1–12 vs month 13–24) or two (time and sex or procedure or ...) categorical covariates are conducted with a logistic regression analysis for part one and a generalized linear model with the log link and gamma distribution for the second part. Marginal means for the combined models are shown on the raw scale (€ per month). 95% confidence intervals in brackets. All estimates reflect cost estimates in Euro (basis year 2011) from a societal perspective.

Differences between the treatment groups are likely to interfere with pre-procedural differences regarding the baseline condition of patients that were not randomly assigned to the different treatment options. Instead, treatment decisions were made by a study-independent “heart team” of cardiac surgeons and cardiologists, which leads to a systematic risk selection [32], but corresponds to current best clinical practice [45]. As a result of this risk selection process, TAVR patients are
considerably older (84.3 vs 80.7 years) and of higher risk according to the logistic EuroSCORE (mean EuroSCORE values TAVR: 19.26, SAVR: 9.83).

Discussion
The goal of the present study was to estimate two-year post-discharge costs of care for TAVR and SAVR-patients. A considerable body of literature is available on the costs of care for TAVR and/or SAVR-patients; however, there are some major limitations: Usually, the length of follow-up in the existing studies is short, and the longer-term follow-up cost estimates are often based on models built from data collected from various sources. Iannaccone and Marwick (2015), for instance, recently reviewed the literature on the cost effectiveness of TAVR and SAVR in recent studies (published between 2012 and 2014) and found a huge range for total follow-up costs for the procedures of $336–$52,529 and $217–$51,992, respectively [46].

Many of the published studies that include follow-up costs use data from the same sources, especially the landmark PARTNER trial [20, 21]. Based on the results of the PARTNER trial, 1-year follow-up cost figures are available for 6 patient groups: Patients considered inoperable were randomly assigned to the treatment options (1) TAVR (N = 179) or (2) no treatment (N = 179). Patients considered at high risk for surgery were randomly assigned to the treatment options (3) Transcatheter
aortic valve replacement via the transfemoral route (TF-TAVR, N = 239) or (4) SAVR (N = 217), or, if not anatomically suitable for TAVR via the TF approach, were randomly assigned to the treatment options (5) Transcatheter aortic valve replacement via the transapical route (TA-TAVR, N = 101) or (6) SAVR (N = 90). Overall, patients in these six treatment groups were comparably old (mean age in years: 83.1, 83.2, 83.9, 84.8, 83.1, 83.4, respectively [21, 47]) and were considered to be at high risk according to the logistic EuroSCORE for the risk selection [32, 49], but corresponds to current best clinical practice [45].

Calculating one-year cost estimates from the predictions shown in Table 2 returns a mean of €10,352 for all patients; €12,068.5 for the TAVR group and €8316.3 for the SAVR group, in 2011 € prices. In contrast, one year post-discharge costs reported in the PARTNER trial are reported in 2010 US dollars and given as $18,856 ($24,787 & $29,289) or in Euro (basis year 2011) from a societal perspective. (DOCX 38 kb)

Collection of patient-level cost data during follow-up is a resource intensive exercise. Since memory is often impaired in elderly patients, it is essential that intervals between telephone interviews are kept as short as possible in order to collect reliable data. Application of standardized unit costs to the data collected in this manner allows for a far more precise estimate of the variability in post-discharge health service resource utilization in this group of patients than the ones given in previous studies.

Please note that there are a number of limitations: First of all, between-group differences in cost measurements should not, or at least only in part, be interpreted as treatment effects, as the different treatment groups are not randomly assigned but subject to a risk-driven patient selection. Secondly, there are substantial decreases in the number of cost measurements over the two year period and we may not assure whether dropouts were entirely noninformative. Finally, the applied temporal categorizations (month 1 vs month 2–24 for in-hospital and outpatient costs) imply the assumption of equal monthly costs between months 2–24.

Despite all these limitations, our results show that it is of major importance to consider country-specific cost estimates for further analysis rather than to solely rely on international evidence such as the PARTNER trial.

Conclusions
Two year post-discharge costs of care are substantially impaired at month 1 post-discharge and in case of death during follow-up. In addition, application of standardized unit costs in combination with monthly patient interviews allows for a far more precise estimate of the variability in post-discharge health service utilization in this group of patients than the ones given in previous studies.

Additional files

Additional file 1: Table S1. Marginal effects for the two parts of the two-part model separately. Marginal effects are shown for the two parts of the two-part model separately. As shown in Table 2, two-part models with one (time: month 1 vs. month 2–24, or month 1–12 vs month 13–24) or two (time and sex or procedure or ...) categorical covariates are conducted with a logistic regression analysis for part one and a generalised linear model with the log link and gamma distribution for the second part. Marginal effects for the combined models are shown on the raw scale (€ per month). 95% confidence intervals in brackets. All estimated prices reflect cost estimates in Euro (basis year 2011) from a societal perspective. (DOCX 38 kb)

Additional file 2: Table S2. Two year monthly cost estimates of patients treated for aortic valve stenosis (including also patients receiving drug-based therapy). Separate two-part models, with one (only time: month 1 vs. month 2–24, or month 1–12 vs month 13–24) or two (time and sex or procedure or ...) categorical covariates are conducted with a logistic regression analysis for part one and a generalised linear model with the log link and gamma distribution for the second part. Marginal effects for the combined models are shown on the raw scale (€ per month). 95% confidence intervals in brackets. All estimated prices reflect cost estimates in Euro (basis year 2011) from a societal perspective. (DOCX 25 kb)

Abbreviations
AS: aortic stenosis; DRUG: control group of the TAVI Calculation of Costs Trial (TCCT) receiving best medical therapy; EuroSCORE: European System for Cardiac Operative Risk Evaluation; GLM: Generalised linear model; PARTNER trial: Placement of Aortic Transcatheter Valve trial; SAVR: Surgical aortic valve replacement; TA-TAVR: Transapical aortic valve replacement; TAVR: Transcatheter aortic valve replacement; TCCT: TAVI Calculation of Costs Trial; TF-TAVR: Transfemoral aortic valve replacement

Acknowledgments
The authors express their gratitude to staff members Melanie Avlar, Jutta Schmitz, Judith Anderl and Christiane Rack for data collection.
Jochen Reinöhl reports personal fees from Edwards Lifesciences and Direct.

The entire study protocol is available in the written consent. No minors participated in the study, since minimum age for inclusion was set at 75 years. Patients or their guardians were informed about the statistical analyses. All authors cooperated in the analysis and interpretation of the results. KK and PH drafted the manuscript, and all authors participated in the revision of the manuscript, approved the final version and agree to be accountable for all aspects of the work.

Ethics approval and consent to participate

The patient data handling and informed consent practice for this research were approved by the Research Ethics Committee Albert-Ludwigs-Universität Freiburg, Germany (52/11). Patients or their guardians were informed about the study details and aims and, if they agreed to participate, provided written consent. No minors participated in the study, since minimum age for inclusion was set at 75 years. The entire study protocol is available in the German Clinical Trials Register (DRKS00000797).

Competing interests

Jochen Reinöhl reports personal fees from Edwards Lifesciences and Direct Flow Medical during the conduct of the study.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1 Institute for Medical Biometry and Statistics, Faculty of Medicine and Medical Center – University of Freiburg, Freiburg im Breisgau, Germany. 2 Department of Cardioiology, Heart Center Freiburg University, Freiburg im Breisgau, Germany. 3 Department of Cardiovascular Surgery, Robert-Bosch-Krankenhaus, Stuttgart, Germany. 4 Clinical Epidemiology, Center for Medical Biometry and Medical Informatics, Medical Center – University of Freiburg, Stefan-Meier-Str. 26, D-79104 Freiburg, Germany.

Received: 18 March 2016 Accepted: 4 July 2017

References

1. Li B, Cairns J, Foitheringham J, Ravanan R. ATTOM study group: predicting hospital costs for patients receiving renal replacement therapy to inform an economic evaluation. Eur J Health Econ. 2015;1–10.
2. Thaden JJ, Nkomo VT, Enriquez-Sarano M. The global burden of aortic stenosis. Prog Cardiovasc Dis. 2014;56:565–71.
3. Jung B, Vahanian A. Epidemiology of acquired valvular heart disease. Can J Cardiol. 2014;30:662–70.
4. Malikar JR, Fontana GP, Jilaihawi H, Kapadia S, Pichard AD, Douglas PS, Thourani VH, Babaliaros VC, Webb JG, Herrmann HC. Transcatheter aortic valve replacement for inoperable severe aortic stenosis. N Engl J Med. 2012;366:1696–704.
5. Wong CY, Green P, Williams M. Decision-making in transcatheter aortic valve replacement: the impact of frailty in older adults with aortic stenosis. Expert Rev Cardiovasc Ther. 2011;3:1761–72.
6. Vahanian A, Alferi O, Al-Attar N, Antunes M, Sax J, Cormier B, Cibier A, De Jaegere P, Fourniau G, Kappelein AP. Transcatheter valve implantation for patients with aortic stenosis: a position statement from the European Association of Cardio-Thoracic Surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2008;29:1463–70.
7. Jung B, Cachier A, Baron G, Messika-Zeitoun D, Delahaye F, Tornos P, Gohlkke-Bänwolf C, Boersma E, Ravaud P, Vahanian A. Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery. Eur Heart J. 2005;26:714–20.
8. Cribier A, Eltchaninoff H, Bash A, Borenstein N, Tron C, Bauer F, Derumeaux G, Anselme F, Laborde F, Leon MB. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis first human case. Circulation. 2002;106:306–8.
9. Reinöhl J, Kaier K, Reinecke H, Schmoo C, Frankenstein L, Vach W, Cribier A, Beyersdorf F, Bode C, Zehender M. Impact of availability of Transcatheter aortic valve replacement on clinical practice. N Engl J Med. 2015;373:2438–47.
10. Moat NE, Ludman P, de Belder MA, Bridgewater B, Cunningham AD, Young CP, Thomas M, Kovac J, Spyt T, MacCarthy PA. Long-term outcomes after Transcatheter aortic valve implantation in high-risk patients with severe aortic stenosis: The UK TAVI (United Kingdom Transcatheter aortic valve implantation) registry. J Am Coll Cardiol. 2011;58:2130–8.
11. Dewey TM, Brown DL, Herbert MA, Culica D, Smith CR, Leon MB, Svensson LG, Tuzcu M, Webb JG, Cribier A. Effect of concomitant coronary artery disease on procedural and late outcomes of transcatheter aortic valve implantation. Ann Thorac Surg. 2010;89:758.
12. Bosmans JM, J K, de Bruyne B, Herijgers P, Dubois C, Legrand V, Verhey G, Rodrigus I. Procedural, 30-day and one year outcome following CoreValve or Edwards transcatheter aortic valve implantation: results of the Belgian national registry. Interact Cardiovasc Thorac Surg. 2011;12:762–7.
13. Babaliaros V, Devreeffy C, Lerasis S, Leonard R, Ittura SA, Maxenmoskis K, Leshnower BG, Guyton RA, Kanitkar M, Keegan P. Comparison of transfemoral transcatheter aortic valve replacement performed in the catheterization laboratory (minimalist approach) versus hybrid operating room (standard approach): outcomes and cost analysis. J Am Coll Cardiol. 2014;7:898–904.
14. Chevreul K, Brunn M, Cadier B, Haour G, Eltchaninoff H, Prat A, Leguenier A, Blanchard D, Fournial G, Jung B. Cost of transcatheter aortic valve implantation and factors associated with higher hospital stay cost in patients of the FRANCE (FRench Aortic CoreValve and Edwards) registry. Archives of Cardiovascular Diseases. 2013;106:209–19.
15. Marcantuono R, Gutsche J, Burke-Julien M, Anwaruddin S, Augoustides JG, Jones D, Margino-Blanchard L, Hoke N, Houserman S, Li R. Rationale, development, implementation, and initial results of a fast track protocol for transfemoral transcatheter aortic valve replacement (TAVR). Catheter Cardiovasc Interv. 2015;85:648–54.
16. Osnnabrugge RL, Head SJ, Genders TS, Van Mieghem NM, De Jaegere PP, van der Boon RM, Kerkvliet JM, Kalesan B, Bogers AJ, Kappetein AP. Costs of transcatheter versus surgical aortic valve replacement in intermediate-risk patients. Eur Heart J. 2012;34:1934–54.
17. Osnnabrugge RL, Speir AM, Head SJ, Fornier CE, Fornier E, Alawadi G, Kappetein AP, Rich JB. Costs for surgical aortic valve replacement according to preoperative risk categories. Ann Thorac Surg. 2013;96:600–6.
18. Reinöhl J, Gutmann A, Kollum M, von zur Mühlen C, Baumbach H, Aivar M, Moser M, Bode C, Zehender M. Transfemoral aortic valve implantation: bleeding events, related costs and outcomes. J Thorim Thorombolysis. 2013;35:469–75.
19. Van Gestel R, De Graeve D, Vrints C, Rodrigus J, Bosmans J. Hospitalization costs ofTAVI in one Belgian university hospital. Acta Cardiol. 2013;68:263–70.
20. Reynolds MR, Magnuson EA, Wang K, Lei Y, Vlavin K, Walczak J, Kodali SK, Lasala JL, O’Neill WW, Davidson CJ. Cost-effectiveness of transcatheter aortic valve replacement compared with standard care among inoperable patients with severe aortic stenosis results from the placement of aortic transcatheter valves (PARTNER) trial (cohort B). Circulation. 2012;125:1102–9.
21. Reynolds MR, Magnuson EA, Lei Y, Wang K, Vlavin K, Li H, Walczak J, Pinto DS, Thourani VH, Svensson LG. Cost-effectiveness of transcatheter aortic valve replacement compared with surgical aortic valve replacement in high-risk patients with severe aortic stenosis: results of the PARTNER (placement of aortic Transcatheter valves) trial (cohort a). J Am Coll Cardiol. 2012;60:263–9.
23. Gutmann A, Kaier K, Sorg S, von zur Mühlen C, Siepe M, Moser M, Geibel A, Zirlik A, Ahrens I, Baumbach H et al: Analysis of the additional costs of clinical complications in patients undergoing transcatheter aortic valve replacement in the German Health Care System. Int J Cardiol 2015;179:231–237.

24. Doble B, Blackhouse G, Goeree R, Xie F: Cost-effectiveness of the Edwards SAPIEN transcatheter heart valve compared with standard management and surgical aortic valve replacement in patients with severe symptomatic aortic stenosis: a Canadian perspective. J Thorac Cardiovasc Surg. 2013;146:52–60.

25. Neyt M, Van Brabant D, Devriese S, Van De Sande S: A cost-utility analysis of transcatheter aortic valve implantation in Belgium: focusing on a well-defined and identifiable population. BMJ Open. 2012;2.e001052.

26. Fairbairn TA, Meads DM, Hulme C, Mather AN, Plein S, Blackman DJ, Doble B, Blackhouse G, Goeree R, Xie F: Cost-effectiveness of transcatheter aortic valve replacement compared with conventional aortic valve replacement in patients ineligible for conventional aortic valve replacement. Heart 2011;heartjnl-2011.

27. Brecker S, Mealing S, Padhiar A, Eaton J, Sculpher M, Bosmans J, Gerckens et al. BMC Health Services Research 2013;14:62–60.

28. Gada H, Agarwal S, Marwick TH: Perspective on the cost-effectiveness of transcatheter aortic valve implantation versus surgical aortic valve replacement in patients with severe aortic stenosis at high operative risk. Heart 2013;99:914–20.

29. Simons CT, Cipriano LE, Shah RU, Garber AM, Owens DK, Hlatky MA: Transcatheter aortic valve replacement in nonsurgical candidates with severe, symptomatic aortic stenosis: a cost-effectiveness analysis. Circ Cardiovasc Qual Outcomes. 2013;6:419–28.

30. Orlando R, Pennant M, Rooney S, Khogali S, Bayliss S, Hassan A, Moore D, Barton P: Cost-effectiveness of transcatheter aortic valve implantation (TAVI) for aortic stenosis in patients who are high risk or contraindicated for surgery: a model-based economic evaluation. Health Technol Assess. 2013;17:1–86.

31. Mullahy J: Much ado about two: reconsidering retransformation and the two-part model in health econometrics. J Health Econ. 1998;17:247–81.

32. Malehi AS, Pourmotahari F, Angali KA: Statistical models for the analysis of healthcare cost data: a literature review. CHE Research Paper. 2005;7.

33. Bock JO, Brettschneider C, Seidl H, Bowles D, Holle R, Greiner W, König HH: Calculation of standardised unit costs from a societal perspective for health economic evaluation. Das Gesundheitswesen. 2015;77:63–61.

34. Mullahy J: Much ado about two: reconsidering retransformation and the two-part model in health econometrics. J Health Econ. 1998;17:247–81.

35. Bock JO, Brettschneider C, Seidl H, Holle R, Greiner W, König HH: Calculation of standardised unit costs from a societal perspective for health economic evaluation. Das Gesundheitswesen. 2015;77:63–61.

36. Mullahy J: Much ado about two: reconsidering retransformation and the two-part model in health econometrics. J Health Econ. 1998;17:247–81.

37. Mullahy J: Much ado about two: reconsidering retransformation and the two-part model in health econometrics. J Health Econ. 1998;17:247–81.

38. Belotti F, Deb P, TPM: Stata module to estimate two-part cross-sectional models. Stata Softw Components. 2013;545:738.

39. Belotti F, Deb P, TPM: Stata module to estimate two-part cross-sectional models. Stata Softw Components. 2013;545:738.

40. Belotti F, Deb P, Manning WG, Norton EC: Two-part models. Stata J. 2015;15:3–20.

41. Li B, Cairns J, Fotheringham J, Ravanin R: ATROM Study Group. Predicting hospital costs for patients receiving renal replacement therapy to inform an economic evaluation. Eur J Health Econ. 2015;16:1–7.

42. Barber J, Thompson S: Multiple regression of cost data: use of generalised linear models. J Health Serv Res Policy. 2004;9:197–204.

43. Mullahy J: Econometric modeling of health care costs and expenditures: a survey of analytical issues and related policy considerations. Med Care. 2005;47:5104–8.